在小细胞肺癌中基蛋白导向剂和MYC
Gerhard Hamilton1, Sandra Stickler1, Barbara Rath1
1Institute of Pharmacology, Medical University of Vienna, Vienna, Austria.
Current cancer drug targets
|January 26, 2024
概括
针对BRD4的新型PROTAC显示出治疗小细胞肺癌 (SCLC) 的前景. ARV-825显示出显著的抗癌作用,可能改善这种侵袭性神经内分泌癌症的化疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 小细胞肺癌 (SCLC) 的预后不好,并且对当前的治疗方法有抗性.
- 瘤抑制剂TP53和RB1经常被禁用,而MYC瘤基因在SCLC中过度表达.
- 直接准MYC是具有挑战性的,因为它的结构和有限的抑制剂有效性.
研究的目的:
- 通过间接针对MYC来探索SCLC的新型治疗策略.
- 研究BET抑制剂,特别是PROTACs对SCLC的疗效.
- 评估ARV-825对SCLC细胞系的抗增殖和细胞毒性作用.
主要方法:
- 讨论了新的BET指导的蛋白质分解向金马 (PROTACs).
- 评估ARV-825,一种特定的BRD4抑制剂.
- 评估SCLC细胞系中的抗增殖和细胞毒性活性.
主要成果:
- 新型BET导向的PROTACs在SCLC中表现出高的抗增殖活性.
- 在SCLC细胞系上,ARV-825显示出优异的细胞毒性作用.
- 抑制BRD4可以减少致癌驱动物MYC的表达.
结论:
- BET抑制剂,特别是像ARV-825这样的PROTACs,代表了SCLC的一个有希望的治疗途径.
- ARV-825可以作为SCLC组合化疗方案的宝贵补充.
- 向BRD4提供了一种间接策略,可以抑制SCLC中MYC驱动的瘤生长.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


